TABLE 2.
Clinicopathologic characteristics for study groups
| LR (n = 126) |
DR (n = 82) |
CR (n = 72) |
No recurrence (n = 218) |
|
|---|---|---|---|---|
| Histology | ||||
| Leiomyosarcoma | 14 (11.1) | 41 (50) | 18 (25) | 58 (26.6) |
| Dedifferentiated liposarcoma | 29 (23) | 7 (8.5) | 14 (19.4) | 22 (10.1) |
| Mixed type/NOS cell liposarcoma | 10 (7.9) | 1 (1.2) | 4 (5.6) | 15 (6.9) |
| Pleomorphic liposarcoma | 10 (7.9) | 2 (2.4) | 6 (8.3) | 7 (3.2) |
| Well-differentiated liposarcoma | 35 (27.8) | 2 (2.4) | 3 (4.2) | 42 (19.3) |
| Undifferentiated pleomorphic sarcoma | 10 (7.9) | 7 (8.5) | 7 (9.7) | 17 (7.8) |
| Sarcoma, NOS | 4 (3.2) | 5 (6.1) | 3 (4.2) | 9 (4.1) |
| Sarcoma, other | 14 (11.1) | 17 (20.7) | 17 (23.6) | 48 (22) |
| Male | 64 (50.8) | 27 (32.9) | 43 (59.7) | 91 (41.7) |
| Age, median (IQR) | 60.0 (20.8) | 64.3 (23.0) | 55.6 (19.1) | 60.2 (21.7) |
| Race | ||||
| Caucasian | 95 (75.4) | 54 (66.7) | 57 (79.2) | 157 (72.7) |
| African American | 7 (5.6) | 14 (17.3) | 6 (8.3) | 26 (12) |
| Latino | 7 (5.6) | 3 (3.7) | 6 (8.3) | 15 (6.9) |
| Asian | 6 (4.8) | 5 (6.2) | 2 (2.8) | 7 (3.2) |
| Other | 2 (1.6) | 2 (2.5) | 0 | 2 (0.9) |
| N/A | 9 (7.1) | 3 (3.7) | 1 (1.4) | 9 (4.2) |
| Functional status | ||||
| Independent | 116 (98.3) | 77 (97.5) | 64 (97) | 200 (96.6) |
| Dependent | 2 (1.7) | 2 (2.5) | 2 (3.0) | 7 (3.4) |
| Tumor size, median (IQR) | 17.5 (16) | 11.8 (11) | 12.3 (12) | 12.5 (13) |
| Final resection status | ||||
| R0 | 49 (39.5) | 55 (67.9) | 48 (67.6) | 136 (64.8) |
| R1 | 67 (54.0) | 24 (29.6) | 19 (26.8) | 61 (29.0) |
| R2 | 8 (6.5) | 2 (2.5) | 4 (5.6) | 13 (6.2) |
| Combined grade | ||||
| Unspecified | 12 (9.8) | 4 (5.1) | 5 (7.8) | 22 (10.6) |
| Low-grade | 42 (34.1) | 9 (11.4) | 11 (17.2) | 77 (37.2) |
| High-grade | 69 (56.1) | 66 (83.5) | 48 (75) | 108 (52.2) |
| Necrosis | 46 (55.4) | 52 (81.3) | 45 (73.8) | 88 (55.3) |
| Lymphovascular invasion | 3 (5.1) | 13 (29.5) | 6 (15.8) | 8 (7.6) |
| Other organ involvement | ||||
| None | 57 (56.4) | 41 (67.2) | 33 (52.4) | 119 (67.6) |
| Adherent | 26 (25.7) | 6 (9.8) | 11 (17.5) | 29 (16.5) |
| Invading | 18 (17.8) | 14 (23) | 19 (30.2) | 28 (15.9) |
| Lymph node positive | 4 (11.1) | 1 (4.5) | 9 (23.1) | 4 (6.7) |
| Multifocal | 29 (23.0) | 36 (43.9) | 30 (41.7) | 0 |
| Surgery | 98 (77.8) | 56 (68.3) | 56 (77.8) | 218 (100) |
| Chemotherapy | 27 (21.4) | 37 (45.1) | 32 (44.4) | 28 (12.8) |
| Radiation therapy | 42 (33.3) | 36 (43.9) | 26 (36.1) | 55 (25.2) |
Abbreviations: CR, combined recurrence; DR, distant recurrence; IQR, interquartile range; LR, local recurrence; N/A, not available; NOS, not otherwise specified.